Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Shares Issued (2020 - 2022)

Candel Therapeutics' Shares Issued history spans 3 years, with the latest figure at $36000.0 for Q4 2022.

  • For Q4 2022, Shares Issued rose 109.11% year-over-year to $36000.0; the TTM value through Dec 2022 reached $64000.0, up 82.86%, while the annual FY2024 figure was $1.7 million, N/A changed from the prior year.
  • Shares Issued for Q4 2022 was $36000.0 at Candel Therapeutics, up from $22000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $375000.0 in Q2 2021 and bottomed at -$395000.0 in Q4 2021.
  • The 3-year median for Shares Issued is $25500.0 (2020), against an average of $16000.0.
  • The largest annual shift saw Shares Issued tumbled 1462.07% in 2021 before it skyrocketed 109.11% in 2022.
  • A 3-year view of Shares Issued shows it stood at $29000.0 in 2020, then crashed by 1462.07% to -$395000.0 in 2021, then surged by 109.11% to $36000.0 in 2022.
  • Per Business Quant, the three most recent readings for CADL's Shares Issued are $36000.0 (Q4 2022), $22000.0 (Q2 2022), and $6000.0 (Q1 2022).